Allakos Inc.
ALLK
|
$1.07
-3.6%
-3.74%
640K
|
Health Technology
(0.0% 1d) (-12.2% 1m) (-73.6% 1y) (0.0% 2d) (0.0% 3d) (-6.9% 7d) (56.26% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 94,025,175
http://www.allakos.com
Sec Filling | Patents | 90 employees
(US) Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood City, CA.
antibody monoclonal antibodies t-cell al002 treatment ceiling
add to watch list Paper trade email alert is off
Press-releases
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
ALLK | $1.07 -3.6% -3.74% 640K
|
Health Technology
|
| O: -1.15%
H: 2.33%
C: 1.55%
business year update financial results
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
ALLK | $1.07 -3.6% -3.74% 640K
|
Health Technology
|
| O: 2.21%
H: 10.07%
C: 5.04%
ak006 cell preclinical
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
ALLK | $1.07 -3.6% -3.74% 640K
|
Health Technology
|
| O: 1.49%
H: 10.29%
C: 2.21%
ak006 publication cell
Allakos Announces a Restructuring to Focus on Development of AK006
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
ALLK | $1.07 -3.6% -3.74% 640K
|
Health Technology
|
| O: -59.2%
H: 10.66%
C: -2.46%
ak006
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
ALLK | $1.07 -3.6% -3.74% 640K
|
Health Technology
|
| O: -59.2%
H: 10.66%
C: -2.46%
urticaria dermatitis trials
Allakos Appoints Neil Graham to its Board of Directors
Published: 2023-08-30 (Crawled : 20:00) - globenewswire.com
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 0.11%
H: 0.0%
C: -1.12%
ASLN | $0.5001 -0.02% -0.02% 200K
|
Health Technology
|
| O: 1.9%
H: 0.93%
C: -0.7%
ALLK | $1.07 -3.6% -3.74% 640K
|
Health Technology
|
| O: 1.02%
H: 5.17%
C: -2.7%
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
Published: 2023-08-02 (Crawled : 20:00) - globenewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -1.6%
H: 0.11%
C: 0.11%
TBIO | $0.3937 -3.98% -4.14% 32K
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -3.79%
H: 0.0%
C: 0.0%
KRYS | $169.695 -2.26% -2.31% 280K
|
Health Technology
|
| O: -2.31%
H: 0.73%
C: -1.14%
EQ | $1.75 -5.41% -5.71% 86K
|
Health Technology
|
| O: 9.59%
H: 7.68%
C: -6.75%
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: 0.02%
H: 0.26%
C: 0.22%
ALLK | $1.07 -3.6% -3.74% 640K
|
Health Technology
|
| O: -0.91%
H: 1.84%
C: -1.1%
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
Published: 2023-06-12 (Crawled : 11:00) - globenewswire.com
ALLK | $1.07 -3.6% -3.74% 640K
|
Health Technology
|
| O: 0.0%
H: 5.21%
C: 2.71%
ak006 cell preclinical
Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
Published: 2023-06-05 (Crawled : 11:00) - globenewswire.com
ALLK | $1.07 -3.6% -3.74% 640K
|
Health Technology
|
| O: 0.0%
H: 0.95%
C: -2.29%
ak006 presentation cell immunology
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
Published: 2023-05-09 (Crawled : 20:00) - globenewswire.com
ALLK | $1.07 -3.6% -3.74% 640K
|
Health Technology
|
| O: 0.46%
H: 5.54%
C: -0.92%
business update financial results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Last 48 Hours Insiders Buying
RMCF | $3.56 -7.2% 7.1K
|
Consumer Non-Durables
|
20:10